Allergy Therapeutics PLC Stock
Your prediction
Pros and Cons of Allergy Therapeutics PLC in the next few years
Pros
?
M***** P*******
?
B****
?
C******** o* t** e**********
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Allergy Therapeutics PLC vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Allergy Therapeutics PLC | - | 0.781% | 10.256% | 89.706% | 10.256% | 171.579% | -31.746% |
| Beximco Pharmaceuticals Ltd. GDR | 0.000% | -26.214% | -15.179% | -11.628% | -15.179% | -21.488% | -63.107% |
| Eledon Pharmaceuticals Inc. | -2.790% | -5.946% | 35.938% | -60.987% | 35.938% | -42.000% | -85.077% |
| SELLAS Life Sciences Group Inc | -3.690% | -11.895% | 12.346% | 148.053% | 12.346% | 2.610% | -36.427% |
News
Stock Market Today, Jan. 29: AT&T Climbs as Earnings Confirm Cash Flow Strength
AT&T (NYSE:T), a provider of wireless, broadband, and fixed-line telecom services, closed Thursday at $25.11, up 4.32%. The stock moved higher after analyst upgrades and a strong fourth-quarter 2025
AT&T's Lumen Deal Hides an Opportunity Most Investors Are Missing
Telecom giant AT&T (NYSE: T) agreed to pay $5.75 billion last year to acquire Lumen's fiber business. The deal, which is expected to close early this year, will add 4 million passed locations and 1
Why AT&T Stock Climbed Today
Shares of AT&T (NYSE: T) popped on Wednesday after the telecommunications titan announced strong subscriber growth metrics.
By the close of trading, AT&T's stock price was up more than 4%.
Image